Antonio Jimeno

University of Denver
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Tumor analysis in mHM and mHM TA . A, Comparison of the average mouse tumor burden on mHM ( n = 27 on nine mice) and mHM TA ( n = 30 on 10 mice) shows that PDX growth on mHM TA is significantly slowed ( P = 0.007, linear mixed-effects model). B, Comparison of tumor volumes also indicates slower PDX growth in mHM TA ( P = 0.003, linear mixed-effects model). For A and B , the marginal fit plus the residuals are plotted for each mouse/tumor at each timepoint are shown as circles. C, PFS (defined as a 20% increase in volume from the starting date) analysis of mHM and mHM TA tumors ( P = 0.0006, cumulative HR). D, Ki67 IHC staining of mHM and mHMTA tumors showing the depth of thickness of living cells surrounding the necrotic tumor core. Magnification is 5×; scales bar, 100 μm. E, Quantification of the depth of these proliferating cells from the tumor edge ( P = 0.048, two-group t test). F, Normalized comparison of mHM and mHM TA tumor volumes reveals a significant reduction in mHM TA ( P = 0.019, two-group t test). G, Likewise, a normalized comparison of mHM and mHM TA live tumor volumes indicates a significant reduction in mHM TA ( P = 0.034, two-group t test). H, A comparison of human CD45 + cell infiltration in the tumors of mHM and mHM TA ( P = 0.743, Wilcoxon rank-sum test). I, A comparison of T-cell infiltration in mHM and mHM TA tumors ( P = 0.468, Wilcoxon rank-sum test). J, IHC of CD3/45+ T cells (indicated by arrows) infiltrating the mHM and mHM TA tumors. Magnification is 40×; scale bar, 50 μm. K, Quantification of human CD45 + lymphocytes within the tumor tissue and capsule indicates increased infiltration within mHM TA tumors ( P = 0.0207, Wilcoxon rank-sum test). L, Quantification of human CD3 + T cells within the tumor tissue and capsule likewise revealed increased infiltration in mHM TA tumors ( P = 0.0107, Wilcoxon rank-sum test). P values: *, ≤0.05; **, ≤0.01; ***, ≤0.001. huCD3, human CD3; huCD45, human CD45.

Year:

2025

In vivo sTO characterization. A, Overview of mHM TA production. Tumor biopsies are implanted as PDXs on NSG mice to expand prior to use in the HM. Patient blood is also drawn at the time of biopsy and reprogrammed into iPSCs and subsequent sTOs, using HLA-A –matched cord blood–derived HSPCs. The sTOs are surgically implanted into the kidney capsule of thymectomized mHM produced with the same HSPCs used to produce the mHM TA . After human peripheral blood cells have been identified in the HM, PDX tissue is implanted into the mHM and mHM TA . B, Picture of a successfully engrafted sTO growing under the kidney capsule, indicated by the yellow arrow. Scale bar, 1 mm. C, Top row (inset): IHC comparison of human thymic tissue with engrafted sTO tissue shows that the sTO tissue expresses both human KRT5 and KRT8. Magnification is 10×; scale bar, 100 ×m. Middle row: Magnified portion of the boxed region in the above sTOs. Columns 1–2, magnification is 20×; scale bar, 50 ×m. Column 3, magnification is 40×; scale bar, 25 μm. Bottom row: Human thymus, for comparison. Magnification is 20×; scale bar, 50 μm. H&E, hematoxylin and eosin. D, Cytometry with all gating of a successfully engrafted sTO shows that the tissue harbors CD4/8 DP T cells undergoing thymic selection and maturation. IHC dual staining of engrafted sTO tissue shows that the tissue harbors CD4/8 DP T cells undergoing thymic selection and maturation. Magnification = 40×; scale bar, 25 μm). Cytometry shows that the tissue harbors CD4/8 DP T cells undergoing thymic selection and maturation. E, MIBI images of an engrafted sTO show that the cellular tissue expresses pan-keratin and ki67, markers of viability. The presence of human CD45 + cells, as well as the expression of HLA class I and HLA-DR proteins, shows its role in immune cell education. F, MIBI images of the sTO also show thymus-specific protein expression. Top row: IDO-1, podoplanin, T-bet, and Tim3. Their merged expression is shown in the final image. Bottom row: Images of sTO-associated T cells, initially showing an overview of the sTO and subsequently an example of a CD3/4+ T cell enlarged in images. The final image is of a nongrafted mouse kidney for comparison of all markers. White scale bar, 100 μm. Red scale bar, 25 μm.

Year:

2025

A fundamental limitation of HLA-A matched humanized mice (mHM), generated with donor hematopoietic stem and progenitor cells and bearing patient-derived xenografts, is that the fidelity of the interaction between the immune system and implanted tumors is limited by lack of thymic T-cell education. We created a model with patient-matched thymic and tumor tissue by using patient peripheral blood mononuclear cells reprogrammed into induced pluripotent stem cells to generate stem cell–derived thymic organoids (sTOs). When implanted in thymectomized mHM, which were subsequently engrafted with patient melanoma tissue (autologous, or mHM TA ), sTOs expressed thymic tissue markers EPCAM, KRT5, and KRT8 and contained developing double-positive T cells. mHM TA had more activated HLA-DR+ T cells in their spleens. Tumor growth in mHM TA was significantly slower compared with mHM, and both tumor volume and viable melanoma content were significantly decreased in mHM TA . This was associated with an increase of intratumoral activated T cells in mHM TA . Whole-exome sequencing followed by intratumoral heterogeneity analysis identified seven candidate neoantigens that were selected against in the mHM TA model, suggesting more effective identification and T cell–driven tumor clearance. This study shows the feasibility of generating patient-specific, thymus-bearing mice and provides a promising new tool in immunology and immunotherapy development. Significance: A humanized mouse xenograft model, in which T cells are educated in a patient-derived implanted thymic organoid autologous to the tumor, provides a more faithful and complete environment to study cancer immunity.

Year:

2025

Changes in intratumoral heterogeneity in mHM TA PDXs can be explained by neoAg selection. A, NeoAg distribution across HLA alleles ( B ) Kullback–Leibler logos show enrichment of hydrophobic amino acids at position 9 in the neoAg pool. The height of each one letter amino acid code is the absolute enrichment relative to unselected peptides. Values above the x axis are positively enriched whereas those below are depleted. C, Distribution of estimated changes in variant allele frequency between the mHM TA and mHM models in all variants identified by exome sequencing. Values to the right of the dotted line represent variants that enriched, or underwent positive selection in mHM TA , whereas values to the left represent variants that underwent negative selection. D, Significant changes between mHM and mHM TA variant allele frequencies are plotted against the predicted HLA binding affinity for nine-mer peptides derived from each variant. The points are colored by which class I HLA molecule the peptide was predicted to bind. All significantly altered variants were found to produce at least two neoAgs. Error bars represent SE. E, Single letter codes for each amino acid are shown with the mutant residue outlined in each. The majority of mutations occurred at TCR contact residue locations (positions 3–8).

Year:

2025

In vitro patient-specific sTO characterization. A, Differentiation of patient-derived iPSCs to TEPs and subsequent production of sTOs. iPSCs are differentiated into TEPs. Coculture of allogeneic (for in vitro examination of the sTOs) or HLA-A –matched HSPCs (for in vivo experiments) at the air–liquid interface produces sTOs with functional TECs. B, qPCR examination of key thymic marker expression in sTOs in vitro . The fold change (2 −ddCt ) in the expression of these genes in sTO cultures at 0-, 3-, and 6-week timepoints was compared with that of undifferentiated iPSCs. Significance was determined using a one-way ANOVA with a Tukey multiple comparison test. cTEC, cortical TEC; mTEC, medullary TEC. C, qPCR examination of tissue-restricted antigen expression in vitro , indicative of AIRE activity, calculated and with significance as determined above. D, IF microscopy of sTOs after 3 weeks of culture shows cell structures expressing thymic markers and identifies presumptive T cells within these structures. DP T cells are indicated by white arrows. Magnification is 40×. Scale bar, 100 μm. E, Cytometry of dissociated sTOs to identify maturing T cells. CD5/7 proT cells were identified after gating CD45 + cells, whereas CD4/8 + T cells were identified after gating CD45 and CD3/TCRαβ cells. P values: *, ≤0.05; **, ≤0.01; *** ≤0.001.

Year:

2025

Examination of T-cell development and activity in the mHM TA . A, Representative cytometry of the human CD45 + cells and HSPCs present in mHM and mHM TA bone marrow. B, Comparison of the average percentage of human CD45 + cells and CD34 + HSPCs within this CD45 + cell population within mHM and mHM TA bone marrow ( P = 0.118 and 0.379, respectively, Wilcoxon rank-sum test). C, Comparison of peripheral human CD45 + lymphocytes in mHM and mHM TA ( P = 0.728, Wilcoxon rank-sum test) and of CD19 + B cells in mHM and mHM TA (0.224, Wilcoxon rank-sum test). D, Cytometric analysis and a comparison of human CD45 + cells, as well as T-cell and B-cell populations, found in the spleens of mHM and mHM TA . E, Comparison of the average human CD45 + cell populations, human T cells, and human B cells on mHM and mHMTA spleens ( P = 0.844, 0.450, and 0.646, Wilcoxon rank-sum test, respectively). F, IFNγ expression was detected in the spleen of both mHM and mHM TA ( P G, Gating and representative cytometry of T cells in mHM and mHM TA show relative populations used to analyze T-cell activation. Purple boxes in the first panels show the T-cell populations gated in the remaining scatter plots. The red boxes show the CD8 + T-cell populations gated for subsequent analysis. H, Representative cytometry of the CD8 + T cells, gated from the red boxes in the previous panel. I, Comparisons of the ratio of HLA-DR + PD1– T cells with all HLA-DR+ T cells shows an increasingly activated T-cell population in mHM TA ( P = 0.0207, two-group t test) and a nonsignificantly increased population of CD4 + T cells. J, Comparison of the HLA-DR + PD1– population with the total HLA-DR+ T-cell population among CD8 + T cells also reveals a trend toward increased activation in mHM TA . P values: *, ≤0.05.

Year:

2025

Background mRNA-2416 is a novel lipid nanoparticle-encapsulated messenger RNA (mRNA) encoding human OX40 ligand (OX40L) for intratumoral (Itu) injection. OX40L plus immune checkpoint inhibitor (ICI) increased preclinical antitumor activity, thus mRNA-2416 plus ICI may potentiate antitumor activity. Methods This first-in-human, phase I/II, open-label, multicenter study examined the safety, tolerability, and efficacy of mRNA-2416 alone (arm A) or with durvalumab (arm B) in patients with advanced solid tumors or lymphoma (NCT03323398). Phase I primary objectives included assessment of safety/tolerability and maximum tolerated dose (MTD)/recommended dose for expansion; phase II arm B dose expansion assessed objective response rate in ovarian cancers. Secondary objectives included pharmacokinetics, disease control rate, duration of response, and progression-free survival (PFS). Assessments of immunologic response to treatment were exploratory. Results From August 2017 to August 2021, 79 patients were enrolled; 61 received treatment (arm A: 39, arm B: 22), including 16 in the expansion cohort. MTD was not reached. Treatment-related emergent adverse events were primarily grade 1/2, with 8 grade 3 and no grade 4/5 events. On-treatment tumor biopsies demonstrated increased OX40L protein expression, elevated PD-L1, and proinflammatory responses. Tumor shrinkage occurred in injected and surrounding non-injected tumors. Median (95% CI) PFS was 60.0 (50.0 to 108.0) and 50.0 (38.0 to 55.0) days for arms A and B, respectively. Conclusions mRNA-2416 alone or with durvalumab was well tolerated. Pharmacodynamic analyses support Itu mRNA proof-of-concept. Predefined primary efficacy endpoints were not met in an exploratory cohort of ovarian cancer. Additional research is warranted to further inform this therapeutic approach.

Year:

2025

Purpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and a PD-1 inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) is a Trop-2–directed antibody-drug conjugate approved for patients with certain previously treated solid tumors. Patients and Methods: TROPiCS-03 (NCT03964727) is an open-label, multicohort, phase II study evaluating SG in advanced solid tumors, including HNSCC. Adults with locally advanced or metastatic HNSCC that progressed following platinum-based chemotherapy and anti–PD-(L)1 therapy [given sequentially (either order) or in combination] were administered SG 10 mg/kg on days 1 and 8 of a 21-day cycle. The primary endpoint was the investigator-assessed objective response rate. Secondary endpoints included duration of response, clinical benefit rate, progression-free survival, overall survival, and safety. Results: Patients ( N = 43) received a median of 3 (range, 2–9) prior anticancer regimens. The objective response rate was 16% [95% confidence interval (CI), 7%–31%], with seven confirmed partial responses. The clinical benefit rate was 28% (95% CI, 15%–44%). The median (95% CI) duration of response, progression-free survival, and overall survival were 4.2 (2.6–not reached), 4.1 (2.6–5.8), and 9.0 (7.1–10.5) months, respectively. The most common treatment-emergent adverse events (TEAE) were diarrhea (47%), nausea (47%), and neutropenia (47%). Grade ≥3 TEAE occurred in 58% of patients. Three patients died from TEAE, with one event (septic shock) considered related to SG. Conclusions: These data demonstrate the clinical potential of Trop-2–directed therapy in managing heavily pretreated patients with advanced HNSCC.

Year:

2025

Purpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and a PD-1 inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) is a Trop-2–directed antibody-drug conjugate approved for patients with certain previously treated solid tumors. Patients and Methods: TROPiCS-03 (NCT03964727) is an open-label, multicohort, phase II study evaluating SG in advanced solid tumors, including HNSCC. Adults with locally advanced or metastatic HNSCC that progressed following platinum-based chemotherapy and anti–PD-(L)1 therapy [given sequentially (either order) or in combination] were administered SG 10 mg/kg on days 1 and 8 of a 21-day cycle. The primary endpoint was the investigator-assessed objective response rate. Secondary endpoints included duration of response, clinical benefit rate, progression-free survival, overall survival, and safety. Results: Patients (N = 43) received a median of 3 (range, 2–9) prior anticancer regimens. The objective response rate was 16% [95% confidence interval (CI), 7%–31%], with seven confirmed partial responses. The clinical benefit rate was 28% (95% CI, 15%–44%). The median (95% CI) duration of response, progression-free survival, and overall survival were 4.2 (2.6–not reached), 4.1 (2.6–5.8), and 9.0 (7.1–10.5) months, respectively. The most common treatment-emergent adverse events (TEAE) were diarrhea (47%), nausea (47%), and neutropenia (47%). Grade ≥3 TEAE occurred in 58% of patients. Three patients died from TEAE, with one event (septic shock) considered related to SG. Conclusions: These data demonstrate the clinical potential of Trop-2–directed therapy in managing heavily pretreated patients with advanced HNSCC.

Year:

2024

Background The programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are validated cancer targets; however, emerging mechanisms and impact of PD-L1 intracellular signaling on cancer behavior are poorly understood. Methods We investigated the cancer cell intrinsic role of PD-L1 in multiple patient-derived models in vitro and in vivo. PD-L1 overexpression, knockdown, and PD-L1 intracellular domain (PD-L1–ICD) deletion (Δ260-290PD-L1) models were assessed for key cancer properties: clonogenicity, motility, invasion, and immune evasion. To determine how PD-L1 transduces signals intracellularly, we used the BioID2 platform to identify the PD-L1 intracellular interactome. Both human papillomavirus-positive and negative patient-derived xenografts were implanted in NOD-scid-gamma and humanized mouse models to investigate the effects of recombinant PD-1, anti–PD-L1, and anti–signal transducer and activator of transcription 3 (STAT3) in vivo. Results PD-L1 intracellular signaling increased clonogenicity, motility, and invasiveness in multiple head and neck squamous cell carcinoma (HNSCC) models, and PD-1 binding enhanced these effects. Protein proximity labeling revealed the PD-L1 interactome, distinct for unbound and bound PD-1, which initiated cancer cell–intrinsic signaling. PD-L1 binding partners interleukin enhancer binding factors 2 and 3 (ILF2-ILF3) transduced their effect through STAT3. Δ260-290PD-L1 disrupted signaling and reversed pro-growth properties. In humanized HNSCC in vivo models bearing T-cells, PD-1 binding triggered PD-L1 signaling, and dual PD-L1 and STAT3 inhibition were required to achieve tumor control. Conclusions Upon PD-1 binding, the PD-L1 extracellular and intracellular domains exert a synchronized effect to promote immune evasion by inhibiting T-cell function while simultaneously enhancing cancer cell–invasive properties.

Year:

2023

Collaborators (9)

Carissa Thomas

The University of Alabama

UNITED STATES
View details

William A. Robinson

Proffessor of Medicine

-

UNITED STATES
View details

Khanh Do

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Theresa Medina

Associate Professor

University of Colorado Cancer Center

UNITED STATES
View details

Stephen Keysar

Assistant Research Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Ammar Sukari

Professor

Karmanos Cancer Institute

UNITED STATES
View details

Holger A. Russ

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

John Morton

Assistant Research Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Dexiang Gao

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details